The AML samples included Down syndrome (DS) and non-DS acute megakaryoblastic leukemia (AMKL; i.e., AML FAB M7), core-binding factor (CBF) AMLs (inv[16] and t[8;21]) and MLL-rearranged AMLs (t[9;11] and t[10;11]). This evidence concerns the gene CEBPZ and acute myeloid leukemia.